Abstract. This research aimed to produce anti-claudin18.2 (CLDN 18.2)/anti-PD-L1 bispecific antibodies to enhance the therapeutic index and expand the responsive population of the parent anti-CLDN ...

Abstract. The BCR-ABL1–negative myeloproliferative neoplasms (e.g., essential thrombocythemia, polycythemia vera, and primary myelofibrosis) are a group of heterogeneous hematologic malignancies that ...

Abstract. Purpose: The high affinity receptor 1 (NTSR1) and its agonist, neurotensin (NTS), are correlated with tumor cell aggressiveness in most solid tumors. As chemoresistance and tumor ...

Remarkable progress made against cancer in the United States is reflected by a 33% decline in the overall cancer mortality rate between 1991 and 2020 (1). Despite this reduction, 2,001,140 new cases ...

2019 Meetings Abstracts: AACR Special Conference on Modernizing Population Sciences in the Digital Age February 19–22, 2019; San Diego, CA Proceedings: AACR Annual Meeting 2019 March 29–April 3, 2019; ...

In May 2009, a summary of the latest assessment of the carcinogenicity of metals, arsenic, dusts, and fibers, including asbestos, by the International Agency for Research on Cancer (IARC) Monograph ...

In 2003, Voskoglou-Nomikos (11) compared published drug activity for 31 cytotoxic cancer drugs where phase II trials, human xenograft, and mouse allograft responses were available for comparison for ...

Patients with FGFR2 -driven cancers derive limited benefit from pan-FGFRi due to multiple FGFR1–4-mediated toxicities and acquired FGFR2 resistance mutations. RLY-4008 is a highly selective FGFR2 ...

Immune checkpoint blockade therapy, one of the most promising forms of cancer immunotherapy, has been successful in multiple cancer types, including invasive urinary bladder cancer, the focus of this ...

Cancer remains one of the leading causes of death globally (1, 2). Immunotherapy has opened a new era of cancer treatment; however, the therapeutic response to immune checkpoint inhibitors (ICI) in ...